Glass House Brands Reports Weak Q1 Results, Announces $50M ATM Program Amid Strategic DEA Registration
GLASF sits 99% above its 52-week low of $4.55.
Summary
Glass House Brands reported weak Q1 financials with increased losses and cash burn, announced a new $50 million ATM program for capital, but also applied for DEA registration to capitalize on medical cannabis rescheduling.
Key Events · Earnings and Guidance · GLASF
-
Weak Q1 Financial Performance
The company reported a net loss of $(17.0) million and negative Adjusted EBITDA of $(4.2) million, both worsening from the prior quarter and year. Operating cash flow was significantly negative at $(11.8) million. Gross profit margin was 25%, missing internal guidance of 29% and down from 45% in Q1 2025.
-
Increased Production Costs
Cost per equivalent dry pound of production rose significantly to $175 in Q1 2026, compared to $129 in Q4 2025 and $108 in Q1 2025, indicating operational inefficiencies or market pressures.
-
New $50 Million At-The-Market (ATM) Program
Glass House Brands established an ATM program to sell up to $50 million of its shares, representing potential dilution of over 7% of its current market capitalization. This provides a flexible capital raising mechanism but adds to dilution risk.
-
DEA Registration for Medical Cannabis Operations
The company has submitted applications for DEA registration to fully operate medical cannabis business under Schedule III Classification, a strategic move to capitalize on recent rescheduling and potentially benefit from 280E tax relief and expanded market access.
Analysis · GLASF · Life Sciences
Glass House Brands reported a challenging first quarter with worsening net losses, negative operating cash flow, and a significant miss on gross profit margin guidance. While revenue slightly exceeded internal expectations, the substantial increase in production costs and declining profitability are concerning. The company also announced a new $50 million At-The-Market (ATM) program, representing potential dilution of over 7% of its current market capitalization, indicating a need for capital. A positive development is the application for DEA registration, positioning the company to benefit from the recent medical cannabis rescheduling, which could offer future tax relief and market expansion.
At the time of this filing, GLASF was trading at $9.04 on OTC in the Life Sciences sector, with a market capitalization of approximately $700.2M. The 52-week trading range was $4.55 to $10.63. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.